Silveira-Moriyama L, Guedes L C, Kingsbury A, Ayling H, Shaw K, Barbosa E R, Bonifati V, Quinn N P, Abou-Sleiman P, Wood N W, Petrie A, Sampaio C, Ferreira J J, Holton J, Revesz T, Lees A J
Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK.
Neurology. 2008 Sep 23;71(13):1021-6. doi: 10.1212/01.wnl.0000326575.20829.45.
Mutations in PARK8 (LRRK2) are associated with autosomal dominant parkinsonism and Parkinson disease (PD). Hyposmia is present in at least 80% of patients with PD and an accumulation of alpha-synuclein (alpha-syn) is seen in the olfactory pathways. In this study we have clinically examined olfaction and pathologically examined the rhinencephalon in individuals carrying the G2019S LRRK2 mutation.
The University of Pennsylvania Smell Test (UPSIT) was used to evaluate the sense of smell in 19 parkinsonian and two asymptomatic carriers of the G2019S mutation and compared with groups of patients with PD and healthy controls. Postmortem examination of alpha-syn accumulation in the rhinencephalon was also carried out in four parkinsonian carriers of the G2019S mutation.
The mean UPSIT score in G2019S parkinsonian carriers was lower than that in healthy controls (p < 0.001) and similar to that found in patients with PD (p > 0.999). Smell tests in two asymptomatic carriers of the G2019S mutation were in the normal range. Postmortem studies of the olfactory pathways in one of the patients who had been clinically tested, and found to have hyposmia, and three other cases with the G2019S mutation, revealed alpha-syn deposition in the olfactory pathways in all cases.
Odor identification is diminished in LRRK2 G2019S mutation parkinsonism but the asymptomatic carriers of the mutation had normal olfaction. We found alpha-syn accumulation with Lewy bodies in the rhinencephalon in all four cases examined pathologically.
PARK8(LRRK2)基因的突变与常染色体显性帕金森综合征及帕金森病(PD)相关。至少80%的帕金森病患者存在嗅觉减退,且在嗅觉通路中可见α-突触核蛋白(α-syn)的积聚。在本研究中,我们对携带G2019S LRRK2突变的个体进行了嗅觉的临床检查,并对其鼻脑进行了病理检查。
使用宾夕法尼亚大学嗅觉测试(UPSIT)对19名帕金森病患者及2名G2019S突变的无症状携带者的嗅觉进行评估,并与帕金森病患者组和健康对照组进行比较。还对4名G2019S突变的帕金森病携带者的鼻脑进行了α-syn积聚的尸检。
G2019S帕金森病携带者的UPSIT平均得分低于健康对照组(p < 0.001),与帕金森病患者的得分相似(p > 0.999)。两名G2019S突变的无症状携带者的嗅觉测试结果在正常范围内。对一名经临床测试发现有嗅觉减退的患者以及其他3名G2019S突变患者的嗅觉通路进行尸检研究,结果显示所有病例的嗅觉通路中均有α-syn沉积。
LRRK2 G2019S突变型帕金森综合征患者的气味识别能力下降,但该突变的无症状携带者嗅觉正常。我们在所有4例经病理检查的病例中均发现鼻脑中存在α-syn积聚及路易小体。